… ProQR annonce des premiers résultats positifs pour l'essai de … CAMBRIDGE, Massachussets, 11 oct. 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq :PRQR), une entreprise dédiée … héréditaires dans son ensemble », a déclaré Stephen R. Russell, M.D., professeur Schrage d'ophtalmologie et des …
… ProQR Announces that QR-010 Meets the Primary Endpoint in a … LEIDEN, the Netherlands, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … results of PQ-010-002 will be presented today by Noreen R. Henig M.D. and John P. Clancy M.D. at the North American …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … to present new data from the InSight study in H2 2021. ProQR’s Presentation Presentation title: Safety and efficacy … Congenital Amaurosis type 10 (LCA10) Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
… ProQR to Present at the Retinal Cell and Gene Therapy … & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Leber congenital amaurosis (LCA10) Presenter: Dr. Stephen R. Russell, Iowa University Presentation type: Oral …
… ProQR to present QR-010 data at the European Cystic Fibrosis … QR-010 can treat all manifestations of CF,” said Noreen R. Henig, MD, Chief Medical Officer of ProQR. “I am very pleased that enrollment of the Phase 1b …
… ProQR Receives Orphan Drug Designation from FDA for Drug … Present Data at two Scientific Conferences Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis … David M. Rodman, MD, Chief Development Strategy Officer of ProQR, “It highlights the unmet need in this devastating …